{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:32:31Z","timestamp":1762252351325},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"EUROPEAN COMMISSION-Horizon 2020\u2fffResearch and Innovation Framework Programme","award":["664561"],"award-info":[{"award-number":["664561"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.phrs.2016.03.017","type":"journal-article","created":{"date-parts":[[2016,3,16]],"date-time":"2016-03-16T22:17:59Z","timestamp":1458166679000},"page":"205-210","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["RAAS inhibition and the course of Alport syndrome"],"prefix":"10.1016","volume":"107","author":[{"given":"Isavella","family":"Savva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alkis","family":"Pierides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantinos","family":"Deltas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4960","key":"10.1016\/j.phrs.2016.03.017_bib0005","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1126\/science.2349482","article-title":"Identification of mutations in the COL4A5 collagen gene in Alport syndrome","volume":"248","author":"Barker","year":"1990","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.phrs.2016.03.017_bib0010","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1681\/ASN.2012020148","article-title":"Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy","volume":"24","author":"Savige","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.phrs.2016.03.017_bib0015","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1681\/ASN.V114649","article-title":"X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males","volume":"11","author":"Jais","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.phrs.2016.03.017_bib0020","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/ki.1993.8","article-title":"Molecular genetics of Alport syndrome","volume":"43","author":"Tryggvason","year":"1993","journal-title":"Kidney Int."},{"issue":"3","key":"10.1016\/j.phrs.2016.03.017_bib0025","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/cge.12258","article-title":"Unbiased next generation sequencing analysis confirms the existence of autosomal dominant Alport syndrome in a relevant fraction of cases","volume":"86","author":"Fallerini","year":"2014","journal-title":"Clin. Genet."},{"issue":"9","key":"10.1016\/j.phrs.2016.03.017_bib0030","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1093\/ndt\/gfp158","volume":"24","author":"Pierides","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"issue":"11","key":"10.1016\/j.phrs.2016.03.017_bib0035","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1681\/ASN.2007040444","article-title":"COL4A3\/COL4A4 mutations producing focal segmental glomerulosclerosis and renal failure in thin basement membrane nephropathy","volume":"18","author":"Voskarides","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.phrs.2016.03.017_bib0040","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1159\/000368519","article-title":"Study of the true clinical progression of autosomal dominant Alport syndrome in a european population","volume":"40","author":"Rosado","year":"2015","journal-title":"Kidney Blood Press. Res."},{"issue":"4","key":"10.1016\/j.phrs.2016.03.017_bib0045","first-page":"177","article-title":"COL4A4 gene study of a European population: description of new mutations causing autosomal dominant Alport syndrome","volume":"5","author":"Rosado","year":"2014","journal-title":"Int. J. Mol. Epidemiol. Genet."},{"issue":"4","key":"10.1016\/j.phrs.2016.03.017_bib0050","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1046\/j.1523-1755.2003.00234.x","article-title":"Thin basement membrane nephropathy","volume":"64","author":"Savige","year":"2003","journal-title":"Kidney Int."},{"issue":"3","key":"10.1016\/j.phrs.2016.03.017_bib0055","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.semnephrol.2005.01.004","article-title":"The clinical features of thin basement membrane nephropathy","volume":"25","author":"Gregory","year":"2005","journal-title":"Semin. Nephrol."},{"issue":"7","key":"10.1016\/j.phrs.2016.03.017_bib0060","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/jama.2011.1141","article-title":"Persistent asymptomatic isolated microscopic hematuria in Israeli adolescents and young adults and risk for end-stage renal disease","volume":"306","author":"Vivante","year":"2011","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.phrs.2016.03.017_bib0065","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group","volume":"329","author":"Lewis","year":"1993","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.phrs.2016.03.017_bib0070","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The angiotensin-converting-enzyme inhibition in progressive renal insufficiency study group","volume":"334","author":"Maschio","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"9069","key":"10.1016\/j.phrs.2016.03.017_bib0075","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)","volume":"349","author":"Randomised placebo-controlled","year":"1997","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.phrs.2016.03.017_bib0080","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"4 Suppl. 1","key":"10.1016\/j.phrs.2016.03.017_bib0085","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.1053\/ajkd.2001.27442","article-title":"A clinical trial in type 2 diabetic nephropathy","volume":"38","author":"Lewis","year":"2001","journal-title":"Am. J. Kidney Dis."},{"issue":"3","key":"10.1016\/j.phrs.2016.03.017_bib0090","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0021-9975(97)80016-3","article-title":"Treatment of X-linked hereditary nephritis in Samoyed dogs with angiotensin converting enzyme (ACE) inhibitor","volume":"117","author":"Grodecki","year":"1997","journal-title":"J. Comp. Pathol."},{"issue":"2","key":"10.1016\/j.phrs.2016.03.017_bib0095","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1046\/j.1523-1755.2003.00779.x","article-title":"Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome","volume":"63","author":"Gross","year":"2003","journal-title":"Kidney Int."},{"issue":"7","key":"10.1016\/j.phrs.2016.03.017_bib0100","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1093\/ndt\/gfh219","article-title":"Antifibrotic: nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis","volume":"19","author":"Gross","year":"2004","journal-title":"Nephrol. Dial. Transplant."},{"issue":"3","key":"10.1016\/j.phrs.2016.03.017_bib0105","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/ajh.2010.231","article-title":"Renal protective effects of aliskiren beyond its antihypertensive property in a mouse model of progressive fibrosis","volume":"24","author":"Gross","year":"2011","journal-title":"Am. J. Hypertens."},{"issue":"6","key":"10.1016\/j.phrs.2016.03.017_bib0110","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s004310051301","article-title":"Enalapril in paediatric patients with Alport syndrome: 2 years\u2fff experience","volume":"159","author":"Proesmans","year":"2000","journal-title":"Eur. J. Pediatr."},{"issue":"3","key":"10.1016\/j.phrs.2016.03.017_bib0115","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00467-003-1366-z","article-title":"Enalapril in children with Alport syndrome","volume":"19","author":"Proesmans","year":"2004","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.phrs.2016.03.017_bib0120","doi-asserted-by":"crossref","first-page":"p2","DOI":"10.1186\/1471-2369-3-2","article-title":"Angiotensin converting enzyme inhibitor therapy in children with Alport syndrome: effect on urinary albumin TGF-beta, and nitrite excretion","volume":"3","author":"Adler","year":"2002","journal-title":"BMC Nephrol."},{"issue":"8","key":"10.1016\/j.phrs.2016.03.017_bib0125","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1093\/ndt\/gfq797","article-title":"Efficacy and safety of losartan in children with Alport syndrome\u2fffresults from a subgroup analysis of a prospective: randomized, placebo- or amlodipine-controlled trial","volume":"26","author":"Webb","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"issue":"5","key":"10.1016\/j.phrs.2016.03.017_bib0130","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00467-012-2372-9","article-title":"Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrome","volume":"28","author":"Webb","year":"2013","journal-title":"Pediatr. Nephrol."},{"issue":"5","key":"10.1016\/j.phrs.2016.03.017_bib0135","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/ki.2011.407","article-title":"Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy","volume":"81","author":"Gross","year":"2012","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.phrs.2016.03.017_bib0140","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000435789","article-title":"Carriers of autosomal recessive Alport syndrome with thin basement membrane nephropathy presenting as focal segmental glomerulosclerosis in later life","volume":"130","author":"Deltas","year":"2015","journal-title":"Nephron"},{"issue":"5","key":"10.1016\/j.phrs.2016.03.017_bib0145","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/cge.12521","article-title":"Collagen type IV-related nephropathies in Portugal: pathogenic COL4A3 and COL4A4 mutations and clinical characterization of 25 families","volume":"88","author":"Nabais Sa","year":"2015","journal-title":"Clin. Genet."},{"issue":"12","key":"10.1016\/j.phrs.2016.03.017_bib0150","doi-asserted-by":"crossref","first-page":"e115015","DOI":"10.1371\/journal.pone.0115015","article-title":"Frequency of COL4A3\/COL4A4 mutations amongst families segregating glomerular microscopic hematuria and evidence for activation of the unfolded protein response. Focal and segmental glomerulosclerosis is a frequent development during ageing","volume":"9","author":"Papazachariou","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.phrs.2016.03.017_bib0155","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/ndt\/gfp551","article-title":"X-inactivation modifies disease severity in female carriers of murine X-linked Alport syndrome","volume":"25","author":"Rheault","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"issue":"8","key":"10.1016\/j.phrs.2016.03.017_bib0160","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/ki.2011.452","article-title":"Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations","volume":"81","author":"Temme","year":"2012","journal-title":"Kidney Int."},{"key":"10.1016\/j.phrs.2016.03.017_bib0165","doi-asserted-by":"crossref","first-page":"436046","DOI":"10.5402\/2012\/436046","article-title":"Safety and efficacy of the ACE-inhibitor ramipril in alport syndrome: the double-blind, randomized, placebo-controlled, multicenter phase III EARLY PRO-TECT Alport trial in pediatric patients","volume":"2012","author":"Gross","year":"2012","journal-title":"ISRN Pediatr."},{"issue":"12","key":"10.1016\/j.phrs.2016.03.017_bib0170","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1007\/s00467-006-0270-8","article-title":"The effect of aldosterone blockade in patients with Alport syndrome","volume":"21","author":"Kaito","year":"2006","journal-title":"Pediatr. Nephrol."},{"issue":"9","key":"10.1016\/j.phrs.2016.03.017_bib0175","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1007\/s00467-013-2490-z","article-title":"Alport syndrome: the effects of spironolactone on proteinuria and urinary TGF-beta1","volume":"28","author":"Giani","year":"2013","journal-title":"Pediatr. Nephrol."},{"issue":"6","key":"10.1016\/j.phrs.2016.03.017_bib0180","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/ki.2009.223","article-title":"Treatment of Alport syndrome: beyond animal models","volume":"76","author":"Gross","year":"2009","journal-title":"Kidney Int."},{"issue":"5","key":"10.1016\/j.phrs.2016.03.017_bib0185","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0002-9440(10)64802-X","article-title":"Integrin alpha1beta1 and transforming growth factor-beta1 play distinct roles in alport glomerular pathogenesis and serve as dual targets for metabolic therapy","volume":"157","author":"Cosgrove","year":"2000","journal-title":"Am. J. Pathol."},{"issue":"4","key":"10.1016\/j.phrs.2016.03.017_bib0190","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1371\/journal.pmed.0030100","article-title":"Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease","volume":"3","author":"Zeisberg","year":"2006","journal-title":"PLoS Med."},{"issue":"2","key":"10.1016\/j.phrs.2016.03.017_bib0195","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1523-1755.2005.00423.x","article-title":"Nephroprotection by antifibrotic and anti-inflammatory effects of the vasopeptidase inhibitor AVE7688","volume":"68","author":"Gross","year":"2005","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.phrs.2016.03.017_bib0200","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1093\/ndt\/gfl810","article-title":"Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome","volume":"22","author":"Koepke","year":"2007","journal-title":"Nephrol. Dial. Transplant."},{"issue":"7","key":"10.1016\/j.phrs.2016.03.017_bib0205","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/nm888","article-title":"BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury","volume":"9","author":"Zeisberg","year":"2003","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.phrs.2016.03.017_bib0210","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1681\/ASN.2004100871","article-title":"Delayed chemokine receptor 1 blockade prolongs survival in collagen 4A3-deficient mice with Alport disease","volume":"16","author":"Ninichuk","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"issue":"11","key":"10.1016\/j.phrs.2016.03.017_bib0215","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1634\/stemcells.2006-0201","article-title":"Bone marrow-derived cells contribute to podocyte regeneration and amelioration of renal disease in a mouse model of Alport syndrome","volume":"24","author":"Prodromidi","year":"2006","journal-title":"Stem Cells"},{"issue":"19","key":"10.1016\/j.phrs.2016.03.017_bib0220","doi-asserted-by":"crossref","first-page":"7321","DOI":"10.1073\/pnas.0601436103","article-title":"Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease","volume":"103","author":"Sugimoto","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.phrs.2016.03.017_bib0225","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/sj.ki.5001521","article-title":"Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice","volume":"70","author":"Ninichuk","year":"2006","journal-title":"Kidney Int."},{"issue":"9","key":"10.1016\/j.phrs.2016.03.017_bib0230","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1681\/ASN.2007070829","article-title":"Irradiation prolongs survival of Alport mice","volume":"19","author":"Katayama","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.phrs.2016.03.017_bib0235","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/ndt\/gfn722","article-title":"Stem cell therapy for Alport syndrome: the hope beyond the hype","volume":"24","author":"Gross","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"issue":"1","key":"10.1016\/j.phrs.2016.03.017_bib0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000020641","article-title":"Animal models of Alport syndrome: advancing the prospects for effective human gene therapy","volume":"8","author":"Heikkila","year":"2000","journal-title":"Exp. Nephrol."},{"issue":"4","key":"10.1016\/j.phrs.2016.03.017_bib0245","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1681\/ASN.2011030243","article-title":"Injection of amniotic fluid stem cells delays progression of renal fibrosis","volume":"23","author":"Sedrakyan","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.phrs.2016.03.017_bib0250","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.matbio.2014.01.006","article-title":"Collagen receptors integrin alpha2beta1 and discoidin domain receptor 1 regulate maturation of the glomerular basement membrane and loss of integrin alpha2beta1 delays kidney fibrosis in COL4A3 knockout mice","volume":"34","author":"Rubel","year":"2014","journal-title":"Matrix Biol."},{"issue":"2","key":"10.1016\/j.phrs.2016.03.017_bib0255","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1681\/ASN.2012121217","article-title":"Evidence for activation of the unfolded protein response in collagen IV nephropathies","volume":"25","author":"Pieri","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"issue":"Suppl. 4","key":"10.1016\/j.phrs.2016.03.017_bib0260","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/ndt\/gfu028","article-title":"Alport syndrome from bench to bedside: the potential of current treatment beyond RAAS blockade and the horizon of future therapies","volume":"29","author":"Gross","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"issue":"2","key":"10.1016\/j.phrs.2016.03.017_bib0265","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/BF00866293","article-title":"Effect of cyclosporin A on proteinuria in patients with Alport\u2fffs syndrome","volume":"6","author":"Callis","year":"1992","journal-title":"Pediatr. Nephrol."},{"issue":"3","key":"10.1016\/j.phrs.2016.03.017_bib0270","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1046\/j.1523-1755.1999.0550031051.x","article-title":"Long-term effects of cyclosporine A in Alport\u2fffs syndrome","volume":"55","author":"Callis","year":"1999","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.phrs.2016.03.017_bib0275","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00467-006-0227-y","article-title":"Cyclosporin therapy in patients with Alport syndrome","volume":"22","author":"Charbit","year":"2007","journal-title":"Pediatr. Nephrol."},{"issue":"3","key":"10.1016\/j.phrs.2016.03.017_bib0280","first-page":"207","article-title":"X-linked, COL4A5 hypomorphic Alport mutations such as G624D and P628L may only exhibit thin basement membrane nephropathy with microhematuria and late onset kidney failure","volume":"17","author":"Pierides","year":"2013","journal-title":"Hippokratia"},{"issue":"3","key":"10.1016\/j.phrs.2016.03.017_bib0285","first-page":"200","article-title":"Co-inheritance of functional podocin variants with heterozygous collagen IV mutations predisposes to renal failure","volume":"130","author":"Stefanou","year":"2015","journal-title":"Nephron-Exp. Nephrol. Genet."},{"issue":"4","key":"10.1016\/j.phrs.2016.03.017_bib0290","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00467-011-2084-6","article-title":"Evidence that NPHS2-R229Q predisposes to proteinuria and renal failure in familial hematuria","volume":"27","author":"Voskarides","year":"2012","journal-title":"Pediatr. Nephrol."},{"issue":"12","key":"10.1016\/j.phrs.2016.03.017_bib0295","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1007\/s00467-008-0934-7","article-title":"The R229Q mutation in NPHS2 may predispose to proteinuria in thin-basement-membrane nephropathy","volume":"23","author":"Tonna","year":"2008","journal-title":"Pediatr. Nephrol."},{"issue":"1","key":"10.1016\/j.phrs.2016.03.017_bib0300","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00467-012-2138-4","article-title":"Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport syndrome research collaborative","volume":"28","author":"Kashtan","year":"2013","journal-title":"Pediatr. Nephrol."},{"issue":"17","key":"10.1016\/j.phrs.2016.03.017_bib0305","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJMoa0902066","article-title":"Strict blood-pressure control and progression of renal failure in children","volume":"361","author":"Group","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.phrs.2016.03.017_bib0310","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S0895-7061(04)00875-1","article-title":"Antihypertensive and renoprotective efficacy and safety of losartan: A long-term study in children with renal disorders","volume":"17","author":"Ellis","year":"2004","journal-title":"Am. J. Hypertens."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661816301943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661816301943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T08:21:38Z","timestamp":1655281298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661816301943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":62,"alternative-id":["S1043661816301943"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2016.03.017","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RAAS inhibition and the course of Alport syndrome","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2016.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}